Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: Interlaboratory variance in the sensitivity of detection and evaluation of scoring systems

Journal of Clinical Pathology

Volumn 53, Issue 2, 2000, Pages 125-130

  Rhodes, A ^a   Jasani, B ^b   Barnes, D M ^c   Bobrow, L G ^d   Miller, K D ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c GUY S HOSPITAL   (United Kingdom)

^d CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Immunohistochemistry; Interlaboratory variation; Oestrogen receptors

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN;

ANALYTIC METHOD; ARTICLE; BREAST CARCINOMA; CANCER HORMONE THERAPY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OBSERVER VARIATION; PRIORITY JOURNAL; PROTEIN DETERMINATION; RELIABILITY; SCORING SYSTEM;

BREAST NEOPLASMS; FALSE NEGATIVE REACTIONS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LABORATORIES; NEOPLASM PROTEINS; QUALITY ASSURANCE, HEALTH CARE; RECEPTORS, ESTROGEN; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SINGLE-BLIND METHOD; TUMOR MARKERS, BIOLOGICAL;

EID: 0033959550     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.53.2.125     Document Type: Article

References (23)

1. 1 Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1598;351:1451-67.
2. 2 Saati TAL, Clamens S, Cohen-Knafo E, et al. Production of monoclonal antibodies to human oestrogen receptor (ER) protein using recombinant ER (RER). Int J Cancer 1993;55:651-4.
3. 3 Hendricks JB, Wilkinson EJ. Comparison of two antibodies for evaluation of estrogen receptors in paraffin-embedded tumours. Mod Pathol 1993;6:765-70.
4. 4 Sannino P, Shousha S. Demonstration of oestrogen receptors in paraffin sections of breast carcinoma using microwave oven processing. J Pathol 1993;170(suppl):201.
5. 5 Kell DL, Kamel OW, Rouse RV. Immunohistochemical analysis of breast carcinoma estrogen and progesterone receptors in paraffin-embedded tissue, correlation of clones ER1D5 and 1A6 with a cytosol-based hormone receptor assay. Appl Immunohistochem 1993;1:275-81.
6. 6 Clark GM, Harvey JM, Osborne CK, et al. Estrogen receptor status determined by immunohistochemistry is superior to biochemical ligand binding assay for evaluating breast cancer patients. Proc Am Soc Clin Oncol 1997;16:129.
7. 7 Leong ASY, Milios J. Comparison of antibodies to oestrogen and progesterone receptors and the influence of microwave antigen retrieval. Appl Immunohistochem 1993;1:282-8.
8. 8 Elledge RM, Osborne CK. Oestrogen receptors and breast cancer: it is time for individualised treatment based on oestrogen receptor status. BMJ 1997;314:1843-44.
9. 9 Elias JM. A phoenix arisen - estrogen receptor immunohistochemistry. J Histotechnol 1997;20:7 10.
10. 10 Barnes DM, Millis RR, Beex LVA, et al. Increased use of immunohistochemistry for oestrogen receptor measurement in mammary carcinoma: the need for quality assurance. Eur J Cancer 1998;34:1677-82.
11. 11 UK NEQAS for Immunocytochemistry. Department of Histopathology, UCL Medical School, Rockefeller Building, University St, London WCIE 6JJ, UK.
12. 12 Reiner A, Nuemeister B, Spona J, et al. Immunocytochemical localisation of oestrogen and progesterone receptors and prognosis in human primary breast cancer. Cancer Res 1990;50:7057-61.
13. 13 Barnes DM, Harris WH, Smith P, et al. Immunohistochemical determination of oestrogen receptors:comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer 1996;74:1445-51.
14. 14 Participation in UK NEQASs. In: UK NEQAS report and directory 1998, 3rd ed. Sheffield: UK NEQAS office, 1998: 15.
15. 15 Pellicer EM, Sundblad A. Evaluation of antibodies to oestrogen receptors. Appl Immunohistochem 1994;2:141.
16. 16 De Mascarel I, Soubeyran I, MacGrogan G, et al. Immunohistochemical analysis of estrogen receptors in 938 breast carcinomas. Concordance with biochemical assay and prognostic signifiance. Appl Immunohitrochem 1995;3:222-31.
17. 17 Pertschuk I.P, Feldman JG, Kim Y-D, et al. Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Spg in frozen sections or cytosol-based ligand-binding assays. Cancer 1996;77:2514 19.
18. 18 Ferno M, Andersson C, Giita F, et al. Oestrogen receptor analysis of paraffin sections and cytosol samples of primary breast cancer in relation to outcome to adjuvant tamoxifen therapy. Acta Oncol 1996;35:17 22.
19. 19 Soubeyran I. Quenel N, Coindre J-M, et al. PS2: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients. Br J Cancer 1996;74:1120-5.
20. 20 Kinsel LB, Szabo E, Greene GL, et al. Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods. Cancer Res 1989;49:1052-6.
21. 21 Allred DC, Harvey JM, Berado M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11:155-68.
22. 22 Barnes DM, Millis RR. Oestrogen receptors: the history, the relevance and the methods of evaluation. In: Kirkham N, Lemoine NR, eds. Progress in pathology 2. Edinburgh: Churchill Livingstone, 1995:89-114.
23. 23 McCarty KS, Miller LS, Cox EB, et al. Estrogen receptor analyses: correlation of biochemical and immunohistochemical methods using monoclonal anti-receptor antibodies. Arch Pathol Lab Med 1985;109:716-21.